Vaccines are considered safe in this population group, although the immune response may be lower than usual in the general population.
Immunocompromised people (including people living with HIV, regardless of the CD4+ count) or people receiving immunosuppressive therapy (including corticosteroids that can be used in the COVID-19 treatment) may have an increased risk of suffering severe COVID-19. No discontinuation of immunosuppressive therapy is recommended.
In the case of vaccines that do not contain live viruses, such as mRNA vaccines and vector vaccines, convalescent plasma or monoclonal antibodies used for COVID-19 treatment would not contraindicate vaccine reception, although to prevent interference with the immune response to the vaccine, it is advisable to delay vaccination at least 90 days.
People who are immunocompromised should receive an additional dose of a COVID-19 vaccine in the primary schedule to provide more opportunity for them to build a sufficient immune response.
Update (March 2023):
Immunocompromised people are among the highest priority groups for which booster doses are recommended.